TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28202067
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (N=61 for each control group)
Study: 28202067
Drug: Acupuncture in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture in addition to standard treatment
Study: 7509509
Drug: 750 anti-factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 anti-factor Xa units of Orgaran given subcutaneously twice-daily
Study: 26181299
Drug: Overall preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall preparation
Study: 16414445
Drug: Fermentable carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermentable carbohydrate (FC) supplementation (40 g/d)
Study: 9299800
Drug: Fluoxetine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine alone
Study: 29921144
Drug: PCIT-ED (Parent-Child
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIT-ED (Parent-Child Interaction Therapy with Emotion Development module)
Study: 21988525
Drug: Behavioural Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural Medicine Rehabilitation (BM)
Study: 11240079
Drug: Treatment-as-usual (CG)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (CG)
Study: 20195472
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPTp) with sulphadoxine‐pyrimethamine (SP)
Study: 7569737
Drug: Iodixanol 320
Normalized name: IODIXANOL 320mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 320 mgI ml‐1
Study: 28382892
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (LNS), 20 g sachet given from 6 to 18 months
Study: 26529126
Drug: Broad spectrum
Normalized name: Broad spectrum penicillin
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Broad spectrum antibiotic treatment
Study: 19388508
Drug: Preload/Coload (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preload/Coload (10 mL/kg before and 10 mL/kg after SAB)
Study: 19388508
Drug: Preload (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preload (20 mL/kg crystalloid infusion before SAB)
Study: 17416261
Drug: Darunavir-ritonavir 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir-ritonavir 600/100 mg twice daily
Study: 17617272
Drug: Lopinavir-ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir-ritonavir 400/100 mg twice daily
Study: 10334150
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide inhalation solution 0.02% (qid)
Study: 7486611
Drug: Dextrorphan HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Dextrorphan (DB14682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrorphan HCl (Ro 01‐6794/706) administered as a loading dose of 200 mg/hr or greater
Study: 7486611
Drug: Dextrorphan HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Dextrorphan (DB14682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrorphan HCl (Ro 01‐6794/706) administered as a loading dose below 200 mg/hr
Study: 28670117
Drug: Dietary beetroot
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary beetroot juice (BR) - 2×70 mL twice daily, each containing 300 mg nitrate
Study: 28670117
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) - 2×70 mL twice daily, nitrate-negligible
Study: 30232958
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of salbutamol/ambroxol fixed-dose combination granules
Study: 9085961
Drug: Intravenous (I.V.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (I.V.) clonidine 4 microg/kg
Study: 27592594
Drug: Daily reminder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily reminder
Study: 27592594
Drug: Daily lottery-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lottery-based incentive
Study: 25623564
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide (5 µg) via Respimat, once daily for 48 weeks
Study: 16150917
Drug: High-dose PYY(3‐36)
Normalized name: PYY(3-36)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PYY(3‐36) (100 nmol/kg)
Study: 16150917
Drug: High-dose GLP‐1(7‐36)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GLP‐1(7‐36) (100 nmol/kg)
Study: 16150917
Drug: Low-dose PYY(3‐36)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PYY(3‐36) (1 nmol/kg) + GLP‐1(7‐36) (10 nmol/kg)
Study: 1814742
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride solution (PS)
Study: 1814742
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride wax-matrix tablets (WMT)
Study: 6235834
Drug: Spironolactone (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50-200 mg daily)
Study: 11293926
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no supplements)
Study: 22932716
Drug: Vorapaxar (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar (2.5 mg daily)
Study: 18030518
Drug: Pre-neoadjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-neoadjuvant chemotherapy (NACT) with silver wire markers for tumor margins
Study: 11988148
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with latex (active treatment)
Study: 10367539
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2/week intravenously diluted in 250 cc of normal saline as 20 minutes infusion for 3 consecutive weeks followed by a 1 week rest period
Study: 10367539
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2/week
Study: 1856249
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (equivalent dose)
Study: 28864708
Drug: Carnosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine (2 g daily in two divided doses)
Study: 19784813
Drug: Therapeutic angiogenesis
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic angiogenesis (gene and cell therapy)
Study: 11813739
Drug: Verbal advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal advice plus written prescription (green prescription)
Study: 10676820
Drug: lesopitron 4‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: lesopitron 4‐80 mg/d
Study: 10676820
Drug: lorazepam 2‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 2‐4 mg/d
Study: 9094885
Drug: Modifications reducing
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Modifications reducing body mass index by 5 kg/m2, quitting a 10 cigarette/d smoking habit, and reducing dietary cholesterol intake by 100 mg/d
Study: 22897460
Drug: Aliskiren/amlodipine 150/5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/amlodipine 150/5mg for 1 week, then up-titration to 300/10 mg for 7 weeks
Study: 18574751
Drug: 20 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mug inhaled procaterol
Study: 11839447
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg gum
Study: 11839447
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsule
Study: 8750368
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg capsule
Study: 11839447
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg capsule
Study: 11839447
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg gum
Study: 11839447
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg gum
Study: 11839447
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg gum (normalized to total drug released)
Study: 11839447
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg gum (normalized to total drug released)
Study: 11839447
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg gum (normalized to total drug released)
Study: 10506315
Drug: Atracurium (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (all doses)
Study: 7672088
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with chlorambucil (CLB)
Study: 7672088
Drug: Deferred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred therapy until progression
Study: 2178298
Drug: AVP antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AVP antagonist [d(CH2)5 Tyr(Me)AVP] 5 micrograms/kg
Study: 31810437
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) - 100 mg/mL formulation, dose range 50 mg to 600 mg per day, titrated over 2 weeks followed by a 2-week assessment period.
Study: 28449630
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly mentioned, assumed to be rocuronium at 0.45 mg/kg)
Study: 7846463
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg melatonin administered at 1200 hours
Study: 27866000
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy without optical fiber
Study: 19815042
Drug: Multi-micronutrient supplements
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-micronutrient supplements
Study: 22120092
Drug: Tolvaptan 15
Normalized name: tolvaptan 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 15 mg/day for 7 days
Study: 15464333
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vardenafil
Study: 21934637
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg vardenafil
Study: 28052576
Drug: 250 mL/day ONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL/day ONS and dietary advice
Study: 26168834
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy (GDFT) with LiDCO rapid system
Study: 26168834
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine fluid therapy)
Study: 9161390
Drug: Nonprotocol use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonprotocol use of antibiotics
Study: 3304371
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (1.5‐15 mg/hr)
Study: 27555168
Drug: Rocuronium (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.9 mg/kg) administered in the MR group (35 patients)
Study: 25496296
Drug: Housing First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing First treatment model
Study: 8160607
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with chest pain present at onset (n = 3000)
Study: 8160607
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis without chest pain present at onset (n = 337)
Study: 3371394
Drug: Conventional metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional metoprolol tablets, 50 mg twice daily
Study: 30477869
Drug: Verum Acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum Acupuncture Group 1 (VA1, 3 times weekly for 4 weeks)
Study: 30477869
Drug: Verum Acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum Acupuncture Group 2 (VA2, twice weekly for 4 weeks)
Study: 30477869
Drug: Sham Acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Acupuncture Group (SA, twice weekly for 4 weeks)
Study: 24135427
Drug: Oral propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol, 2 mg/kg/day
Study: 24135427
Drug: Topical propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical propranolol 1% ointment twice daily
Study: 24135427
Drug: Intralesional propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional propranolol, 1 mg in 1 ml injection once weekly
Study: 11518628
Drug: Topiramate medium
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate medium dosage (200 mg daily)
Study: 7950197
Drug: Mixture ATP
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture ATP (General therapy)
Study: 28545400
Drug: Behavioural medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural medicine intervention in physiotherapy (goal-setting, self-monitoring, feedback) for 4 months
Study: 15948916
Drug: Clinical drug
Normalized name: Product containing precisely paracetamol 1 gram/1 each prolonged-release oral tablet (clinical drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical drug trial
Study: 2814916
Drug: Cyclosporine administered
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine administered orally twice a day (9 a.m. and 21 p.m.)
Study: 791234
Drug: Promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 25 mg plus Ephedrine 12.5 mg
Study: 791234
Drug: Promethazine 12.5
Normalized name: promethazine 12.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 12.5 mg plus Ephedrine 25 mg
Study: 29266524
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive rehabilitation therapy program (eReCog)
Study: 21796707
Drug: Curcumin 500
Normalized name: curcumin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 500 mg/day
Study: 21796707
Drug: Curcumin 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 6 g/day
Study: 16431893
Drug: ARB (Angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (Angiotensin II-receptor blockers)
Study: 16431893
Drug: CCB (Calcium-channel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB (Calcium-channel blocker)
Study: 12908681
Drug: Propofol (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.0 mg x kg(‐1) i.v.)
Study: 10884325
Drug: GABA(A) receptor
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA(A) receptor subtypes immunohistochemically analyzed with subunit‐specific antibodies (alpha1, alpha2, alpha3, beta2,3, and gamma2)
Study: 10884325
Drug: GABA(A) receptor
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA(A) receptor subunit staining
Study: 10884325
Drug: GABA(A) receptor
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA(A) receptor alpha2‐subunit
Study: 10884325
Drug: GABA(A) receptor
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA(A) receptor alpha1‐subunit
Study: 10884325
Drug: GABA(A) receptor
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA(A) receptor beta2,3- and gamma2-subunits
Study: 17926625
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (control)
Study: 24016491
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing (using clinical information plus genotype)
Study: 24016491
Drug: Clinical-guided dosing
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical-guided dosing (using only clinical information)
Study: 21397626
Drug: Citicoline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline treatment for 8 weeks
Study: 18313446
Drug: Ultralow-dose transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralow-dose transdermal estradiol (0.014 mg/day)
Study: 16983107
Drug: Simultaneous chemoradiotherapy
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous chemoradiotherapy (paclitaxel 60 mg/m2 weekly)
Study: 16331853
Drug: Hospital-based medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based medical day-treatment program
Study: 16331853
Drug: Community-based nonmedical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based nonmedical day treatment programs
Study: 11386894
Drug: Warfarin in
Normalized name: warfarin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin in clinical practice
Study: 9041624
Drug: Cefixime (CFX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (CFX; 8 mg/kg once daily)
Study: 9041624
Drug: Amoxicillin/clavulanate (A/C;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (A/C; 40 mg/kg/day in three divided doses)
Study: 9041624
Drug: Amoxicillin/clavulanate (A/C)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (A/C)
Study: 28668857
Drug: Reiki treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reiki treatment
Study: 29701561
Drug: G‐CSF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (300 μg/day, 7 subcutaneous administrations over 1 week)
Study: 28087128
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (8 days/40 IU twice daily)
Study: 28087128
Drug: Placebo (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 days/10 puffs twice daily)
Study: 20621520
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin if PGL was >10.0 mmol/L (>180 mg/dL) (control group [CG]), n=24
Study: 20621520
Drug: 24-hour intravenous
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour intravenous (IV) insulin infusion (ISI)
Study: 12963171
Drug: Cyclic oral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic oral regimen of norethisterone acetate (1 mg on day 13‐22) and estradiol (days 1‐21; 2 mg, days 22‐28; 1 mg)
Study: 6380212
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg/kg)
Study: 26120981
Drug: Cytoflavin (10ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (10ml of the solution in one injection once a day in 200 ml of isotonic solution of sodium chloride intravenously in drops in the morning during 10 days)
Study: 26120981
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (nonsteroid anti‐inflammatory drugs, myorelaxants, vitamins)
Study: 23927582
Drug: Levofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (750 mg/day)
Study: 11876707
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg/day)
Study: 18469158
Drug: Once-weekly epoetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly epoetin alfa
Study: 18469158
Drug: Control (twice-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (twice- or thrice-weekly epoetin alfa)
Study: 12677616
Drug: Single-stimulation infraclavicular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-stimulation infraclavicular brachial plexus block (ICB) with 40 mL of ropivacaine 0.75%
Study: 12677616
Drug: Triple-stimulation axillary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-stimulation axillary block (AxB) with 40 mL of ropivacaine 0.75%
Study: 1873424
Drug: Oral tilidine-naloxone
Normalized name: naloxone / tilidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tilidine-naloxone
Study: 30862999
Drug: Meal replacement
Normalized name: Diabetic meal replacement bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal replacement group (MR-G) with soy-yogurt-honey preparation
Study: 21296862
Drug: rhG-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhG-CSF (10 µg/kg/day intravenous infusion once daily for 5 days)
Study: 16392976
Drug: Voucher for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voucher for free methadone maintenance treatment (MMT)
Study: 3440773
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate lozenges (23 mg)
Study: 3440773
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo lozenges
Study: 31429599
Drug: Resveratrol (RV)
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (RV) 330 mg, 3 times a day for 3 days plus an additional 330 mg on the morning of the fourth day.
Study: 23784266
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg coadministered with quinidine 300 mg (n = 42)
Study: 23784266
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg coadministered with verapamil 240 mg (n = 34)
Study: 23784266
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg coadministered with digoxin 0.25 mg (n = 48)
Study: 23784266
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg coadministered with atorvastatin 80 mg (n = 32)